Beta Bionics (BBNX) Stock Overview
A commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BBNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Beta Bionics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.20 |
| 52 Week High | US$32.71 |
| 52 Week Low | US$8.80 |
| Beta | 0 |
| 1 Month Change | -22.10% |
| 3 Month Change | -34.00% |
| 1 Year Change | -33.19% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.07% |
Recent News & Updates
Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Beta Bionics: Speculative Appeal After An Eventful Start To The Year
Summary Beta Bionics shares have plunged over two-thirds since December, driven by disappointing 2026 guidance and slowing momentum. BBNX's 2026 revenue guidance of $130–$135 million signals minimal growth from Q4’s annualized $128 million, raising concerns about sustained operational losses. Despite $265 million in net cash, BBNX trades at just over 1x sales, reflecting deep investor skepticism and speculative appeal after severe multiple compression. FDA warnings and competitive risks further pressure sentiment, but current valuation appears de-risked, offering speculative upside if growth reaccelerates. Read the full article on Seeking AlphaRecent updates
Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Beta Bionics: Speculative Appeal After An Eventful Start To The Year
Summary Beta Bionics shares have plunged over two-thirds since December, driven by disappointing 2026 guidance and slowing momentum. BBNX's 2026 revenue guidance of $130–$135 million signals minimal growth from Q4’s annualized $128 million, raising concerns about sustained operational losses. Despite $265 million in net cash, BBNX trades at just over 1x sales, reflecting deep investor skepticism and speculative appeal after severe multiple compression. FDA warnings and competitive risks further pressure sentiment, but current valuation appears de-risked, offering speculative upside if growth reaccelerates. Read the full article on Seeking AlphaBeta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
The Beta Bionics, Inc. ( NASDAQ:BBNX ) share price has fared very poorly over the last month, falling by a substantial...
Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?We're Hopeful That Beta Bionics (NASDAQ:BBNX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Beta Bionics, Inc. (NASDAQ:BBNX) Looks Just Right With A 35% Price Jump
Despite an already strong run, Beta Bionics, Inc. ( NASDAQ:BBNX ) shares have been powering on, with a gain of 35% in...Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Beta Bionics: Slowing Down Or Being Conservative?
Summary Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure. With substantial net cash holdings, the stock remains interesting if the guidance is conservative, offering potential upside given the current low valuation. Read the full article on Seeking AlphaBeta Bionics: A Sugar Rush For This IPO
Summary Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company’s iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years. While the growth is compelling, risks include competition, reliance on partners, and the single-product nature, making me cautious about initiating a position now. Read the full article on Seeking AlphaShareholder Returns
| BBNX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -12.4% | -2.5% | 1.1% |
| 1Y | -33.2% | -22.9% | 26.7% |
Return vs Industry: BBNX underperformed the US Medical Equipment industry which returned -22.5% over the past year.
Return vs Market: BBNX underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| BBNX volatility | |
|---|---|
| BBNX Average Weekly Movement | 10.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BBNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BBNX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 422 | Sean Saint | www.betabionics.com |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
Beta Bionics, Inc. Fundamentals Summary
| BBNX fundamental statistics | |
|---|---|
| Market cap | US$429.13m |
| Earnings (TTM) | -US$66.44m |
| Revenue (TTM) | US$110.24m |
Is BBNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBNX income statement (TTM) | |
|---|---|
| Revenue | US$110.24m |
| Cost of Revenue | US$47.24m |
| Gross Profit | US$63.00m |
| Other Expenses | US$129.44m |
| Earnings | -US$66.44m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 57.15% |
| Net Profit Margin | -60.27% |
| Debt/Equity Ratio | 0% |
How did BBNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 01:38 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beta Bionics, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |